Key result
This article reviews newer therapies for the treatment of stable ischemic heart disease, with a special focus on managing patients with refractory angina.
This review summarizes newer therapeutic options for managing stable ischemic heart disease, particularly for patients with refractory angina despite standard medical management and revascularization.
May aid refractory angina management when standard options fail; leaves open the need for randomized validation of efficacy and safety.
Ischemic heart disease remains a major public health problem nationally and internationally. Stable ischemic heart disease (SIHD) is one of the clinical manifestations of ischemic heart disease and is generally characterized by episodes of reversible myocardial demand/supply mismatch, related to ischemia or hypoxia, which are usually inducible by exercise, emotion, or other stress and reproducible-but which may also be occurring spontaneously. Improvements in the treatment of acute coronary syndromes along with increasing prevalence of cardiovascular risk factors, including diabetes and obesity, have led to increasing population of patients with SIHD. A significant number of these continue to have severe angina despite medical management and revascularization procedures performed and may progress to refractory angina. This article reviews the newer therapies in the treatment of SIHD with special focus in treating patients with refractory angina.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2015) conducted a review in Stable ischemic heart disease and refractory angina. Newer therapies was evaluated. This article reviews newer therapies for the treatment of stable ischemic heart disease, with a special focus on managing patients with refractory angina.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: